According to FutureWise analysis the market for Neuroendocrine Carcinoma Treatment in 2023 is US$ 1.84 billion, and is expected to reach US$ 3.46 billion by 2031 at a CAGR of 8.22%.
Neuroendocrine tumor is a malignant and a rare disorder that covers over one percent of all the malignant disorders. Neuroendocrine carcinoma develops in different organs like intestines, kidneys, lungs, GI tract and brain. This cancer type occurs in the neuroendocrine system of humans and produces hormones that are like neuroendocrine cells. As per the America Society of Clinical Oncology, over 11,000 people in the United States are diagnosed with neuroendocrine carcinoma every year. Furthermore, as pe the U.S Surveillance Epidemiology and End Results Register, the prevalence of gastrointestinal neuroendocrine carcinoma has risen by over 300% as compared to 1981, thus offering an opportunity for neuroendocrine carcinoma treatment market growth. Additionally, growing investments in research and development for creating next-gen sequencing tools that are cost-effective and are used for developing advanced cancer therapies. With an increase in the number of clinical trials, this market is anticipated to witness substantial growth over the next few years.
There are various treatment alternatives available for the neuroendocrine carcinoma like radiation therapy, chemotherapy and surgery. 5-Fluorouracil and Streptozocin are some of the drugs that are used for treating this cancer. Many key players are constantly making efforts in developing targeted therapies, thereby propelling the proliferation of the market. Targeted drugs like Sunitinib and Everolimus are used for the treatment of this cancer. Such a variety of drug alternatives for treatment shall bolster the proliferation of the market.